12:35 , May 8, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
13:52 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

KLRG1 inhibition to treat breast cancer, colorectal cancer and melanoma

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; colorectal cancer; melanoma Mouse studies suggest inhibiting KLRG1 could help treat breast cancer, colorectal cancer and melanoma. In a mouse model of metastatic breast cancer, a mAb against mouse...
02:22 , Apr 5, 2019 |  BC Innovations  |  Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
19:01 , Oct 26, 2018 |  BC Week In Review  |  Company News

AstraZeneca gets rights, options to Innate immuno-oncology therapies

AstraZeneca plc (LSE:AZN; NYSE:AZN) expanded its next generation immuno-oncology pipeline on Oct. 23, gaining rights and options to a basket of therapies from Innate Pharma S.A. (Euronext:IPH). In return, Innate gained U.S. and European commercialization...
23:17 , Oct 23, 2018 |  BC Extra  |  Company News

AstraZeneca gets rights, options to basket of next-gen immuno-oncology therapies from Innate

AstraZeneca plc (LSE:AZN; NYSE:AZN) expanded its next generation immuno-oncology pipeline on Tuesday, gaining rights and options to a basket of therapies from Innate Pharma S.A. (Euronext:IPH). In return, Innate gained U.S. and European commercialization rights...
18:06 , Oct 19, 2018 |  BC Week In Review  |  Company News

Xyphos, Parker Institute steer next-gen Car T therapies into solid tumors

Xyphos Biosciences Inc. (South San Francisco, Calif.) will partner with the Parker Institute for Cancer Immunotherapy to develop CAR Ts using Xyphos' convertible CAR platform. Xyphos President and CEO Jim Knighton told BioCentury the research...
00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...